| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Bjornbom, E., et al.
(författare)
-
Reduction of NOx with NH3 in presence of pyrolysed macro-cycle catalyst
- 1991
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Reduction of NOx with NH3 in the presence of pyrolyzed cobalt-tetraphenylporphyrin, CoTPP 'macro-cycle black', was studied. Active carbon, Norit RBXS 1, was used as a carrier. The experimental conditions were varied as follows: temperature from 95 to 140°C, space velocity of the gas mixture 1000-5000 h-1 and catalyst content 0-1%. The results showed that, in the experimental range studied, the temperature has no significant effect on the conversion of NOx. The conversion of NOx at low space velocity of the gas (1000 h-1) was high (approx. 90%), both in the presence and absence of CoTPP black. This was explained by the fact that the active carbon used as a catalyst support also has a catalytic effect on the reduction of NOx. At low space velocity this effect is sufficient to achieve high conversion of NOx in the presence of active carbon only. The conversion decreased at higher space velocity, however. The presence of CoTPP black counteracted the negative effect of the increased space velocity. The effect of the 'macro-cycle black' on the conversion of NOx was significant at higher space velocitites.
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
